ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: John Young to Leave NCI for ELM; Yates Looking for Chief Of Outpatient Services At RPI

March 18, 1988

Pharmacia Says SU5416 Doesn’t Benefit Colorectal Cancer Patients, Closes Trial.

March 1, 2002

Change In Method Of Counting Cancer Incidence Results In More Attributed To Work Hazards

October 6, 1978

Advocacy. Bypass Budget Treated As Serious Funding Request By Advocates

January 30, 1998

DCE Recompetition Of Human Tissue Procurement Approved

November 23, 1990

Olaparib Study Demonstrates No Changes In Overall Survival

March 30, 2012